Theranostics refers to a medical approach combining diagnosis and treatment around the same biological target. In nuclear medicine, it takes a particularly accomplished form: a radiotracer identifies the target through imaging, then a therapeutic radioligand uses the same target to deliver personalized treatment.
Targeted radionuclide therapy (RIV) is a nuclear medicine treatment approach that uses a targeted radiopharmaceutical to deliver radiation directly inside diseased cells or tissues. The treatment combines a carrier molecule, capable of recognizing a specific biological target, with a therapeutic radioactive isotope, enabling selective irradiation of the disease from inside the body.
RIV is the major therapeutic application of theranostics in nuclear medicine.
These terms are brought together to help readers navigate French and international resources. They describe related approaches whose scope depends on the context.
RIV is the French abbreviation for “radiothérapie interne vectorisée”, defined above. Here it refers to targeted radionuclide treatments.
Radioligand therapy (RLT) uses a radiolabelled ligand; the cited guideline describes ligands targeting PSMA. [1]
Peptide receptor radionuclide therapy (PRRT) uses a radiolabelled peptide targeting a receptor, notably somatostatin receptors (SSTR). [2]
The target, radiopharmaceutical and clinical context need to be specified: these abbreviations alone do not define an indication.
PSMA and SSTR provide examples linking the terminology to existing resources. Use the sections below to explore targets, recommendations and clinical research.
These references document the RLT/PRRT chapter. They do not validate centre counts, trial counts or maturity figures elsewhere on this page. The years below are the publication years.
Reference content from the original site. Dates and statuses reflect the sources; no new scientific verification has been performed.
Browse the directory